Menu

Becton, Dickinson and Company BDX

Full chart Compare
Set alert

Price alert · BDX

All alert types
213.21 USD -0.28 (-0.13%)

Nov 6, 2026, 9:57 AM EST

211.66 Day range 213.67
139.46 52-week range 213.55
YTD
+39.75%
1 year
+52.88%
Market cap
58.15B
Revenue (ttm)
22.48B
Profit margin
4.19%
EPS (ttm)
5.06
Shares out
272.39M
P/E ratio
42.19
Forward P/E
15.02
Dividend
4.20 (2.12%)
Ex-dividend date
Sep 8, 2026
YTD return
+39.75%
1-year return
+52.88%
Volume
221.79K
Avg volume
1.78M
Open
212.02
Previous close
213.50
Day's range
211.66 – 213.67
52-week range
139.46 – 213.55
Beta
0.28
Analysts
Buy
Price target
195.57 (-8.3%)
Earnings date
Nov 5, 2026

5D +15.19 (+7.66%)

200210MonTueWedThuFri213.48

Key statistics

Enterprise value
73.08B
PEG ratio
1.11
Price / sales
2.58
Price / book
2.38
Dividend yield
2.01%
Payout ratio
72.49%
Revenue growth
5.40%
Free cash flow
4.48B
Total cash
709.00M
Total debt
16.81B
Return on equity
6.61%
Short % of float
3.73%
50-day average
187.27
200-day average
166.58

Financials — quick view

All financials
BDX Revenue — quarterly 4.98B
2022-Q4 20222023-Q1 20222023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20252026-Q2 20262026-Q3 2026
BDX Net income — quarterly 377.00M
2022-Q4 20222023-Q1 20222023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20252026-Q2 20262026-Q3 2026
BDX EPS — quarterly 1.37
2022-Q4 20222023-Q1 20222023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20252026-Q2 20262026-Q3 2026

Earnings

BDX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Sep 30, 20264.07———
Aug 6, 2026Jun 30, 20263.143.23+0.09+2.87%
May 7, 2026Mar 31, 20262.782.90+0.12+4.32%
Feb 9, 2026Dec 31, 20252.212.91+0.70+31.67%
Nov 6, 2025Sep 30, 20253.923.96+0.04+1.02%
Aug 7, 2025Jun 30, 20253.403.68+0.28+8.24%

Upgrades / downgrades

BDX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 7, 2026Barclaysinit—Underweight
Aug 31, 2026B of A SecuritiesmainNeutralNeutral
Aug 13, 2026RBC CapitalmainSector PerformSector Perform
Aug 7, 2026CitigroupmainBuyBuy
Aug 7, 2026RBC CapitalmainSector PerformSector Perform
Aug 7, 2026Piper SandlermainNeutralNeutral

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States
Website
bd.com

News

Your note

Sign in to keep a note on BDX — it syncs with the Stock Master app.

Insider holders

BDX insider holders
InsiderRelationLatest transactionDateShares held
DELOREFICE CHRISTOPHERChief Financial OfficerStock Award(Grant)Nov 25, 202522,982
FELD MICHAELOfficerSaleOct 25, 202619,568
FRASER CLAIREDirectorSaleSep 9, 202522,226
GOETTE ROLANDOfficerSaleAug 10, 202616,635
JONES CHRISTOPHER IAN MONTAGUEDirectorStock Award(Grant)Jan 26, 202624,304
MUHSIN BILALOfficerStock Award(Grant)Jun 30, 202641,359

Institution ownership

BDX institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.93%24,592,1665.24BJun 29, 2026
Vanguard Capital Management LLC6.53%17,987,8343.83BJun 29, 2026
State Street Corporation5.44%15,000,0643.19BJun 29, 2026
Vanguard Portfolio Management LLC5.43%14,974,1363.19BJun 29, 2026
First Eagle Investment Management, LLC5.01%13,815,3352.94BJun 29, 2026
Invesco Ltd.3.23%8,898,4881.90BJun 29, 2026

Fund ownership

BDX fund ownership
Holder% heldSharesValueReported
First Eagle Funds-First Eagle Global Fund3.32%9,151,9951.95BJul 30, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%8,747,2611.86BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%7,136,0261.52BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund2.17%5,970,1671.27BJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.32%3,629,584772.96MSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.28%3,539,936753.86MSep 29, 2026